See more : Kawasaki Kisen Kaisha, Ltd. (KAKKF) Income Statement Analysis – Financial Results
Complete financial analysis of Biotech Acquisition Company (BIOTU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biotech Acquisition Company, a leading company in the Shell Companies industry within the Financial Services sector.
- LIV Capital Acquisition Corp. (LIVK) Income Statement Analysis – Financial Results
- Sdiptech AB (publ) (SDTHF) Income Statement Analysis – Financial Results
- Entrée Resources Ltd. (ERLFF) Income Statement Analysis – Financial Results
- Red Mountain Mining Limited (RMX.AX) Income Statement Analysis – Financial Results
- Aegean Airlines S.A. (AEGN.AT) Income Statement Analysis – Financial Results
Biotech Acquisition Company (BIOTU)
Industry: Shell Companies
Sector: Financial Services
About Biotech Acquisition Company
Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 1.57M | 0.00 |
| Gross Profit | -1.57M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 |
| Other Expenses | 1.57M | 0.00 |
| Operating Expenses | 1.57M | 0.00 |
| Cost & Expenses | 1.57M | 0.00 |
| Interest Income | 21.30K | 0.00 |
| Interest Expense | 5.29M | 0.00 |
| Depreciation & Amortization | -5.29M | 206.30K |
| EBITDA | -6.86M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -1.57M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.29M | 0.00 |
| Income Before Tax | -6.86M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 5.29M | 0.00 |
| Net Income | -12.16M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -0.42 | 0.00 |
| EPS Diluted | -0.42 | 0.00 |
| Weighted Avg Shares Out | 28.75M | 28.75M |
| Weighted Avg Shares Out (Dil) | 28.75M | 28.75M |
Biotech Acquisition Company Announces Separate Trading of its Class A Ordinary Shares and Warrants Commencing March 18, 2021
Biotech Acquisition Company Announces Closing of $230,000,000 Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports